<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904536</url>
  </required_header>
  <id_info>
    <org_study_id>X21-0113</org_study_id>
    <nct_id>NCT04904536</nct_id>
  </id_info>
  <brief_title>Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy</brief_title>
  <acronym>STRONGER</acronym>
  <official_title>An International, Investigator Initiated and Conducted, Pragmatic Clinical Trial to Determine Whether 40mg Atorvastatin Daily Can Improve Neurocognitive Function in Adults With Long COVID Neurological Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Alfred</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad del Desarrollo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      STRONGER is an international, investigator initiated and conducted, pragmatic clinical trial&#xD;
      to determine whether 40mg atorvastatin daily can improve neurocognitive function in adults&#xD;
      with long COVID neurological symptoms. The objective is to determine effectiveness of&#xD;
      treatment with 40mg atorvastatin over 18 months on attenuating cognitive decline and&#xD;
      neuroinflammatory biomarkers in adults with long COVID neurological symptoms. The study&#xD;
      design is a prospective, randomised, open-label, blinded endpoint (PROBE) study of&#xD;
      atorvastatin 40mg on top of standard care, in patients with long COVID neurological symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Question: Does treatment with 40mg atorvastatin over 18 months attenuate cognitive decline&#xD;
      and neuroinflammatory biomarkers in adults with long COVID neurological symptoms? Aims: In&#xD;
      410 adults who report ongoing alteration of their memory, thinking, concentration or mood&#xD;
      after COVID-19 diagnosis, this pragmatic clinical trial aims to determine the effects of&#xD;
      standard-dose atorvastatin on improving neurological outcomes with sensitive measures of&#xD;
      cognitive function and brain MRI.&#xD;
&#xD;
      Outcome measures include; Primary - processing speed, assessed on the oral Symbol Digit&#xD;
      Modalities Test (SDMT). Key Secondary - white matter free water measured on diffusion MRI&#xD;
      brain imaging. Other - other components of cognitive function; other health assessments;&#xD;
      other MRI markers of cerebral white matter integrity, iron load, cerebral perfusion, and&#xD;
      glutathione for oxidative stress; cost-effectiveness compared to standard care. The study&#xD;
      sites will be established at centralised research clinics located at: The Brain and Mind&#xD;
      Centre of the University of Sydney; Alfred Medical Centre linked to Monash University, and a&#xD;
      research clinic associated with Clínica Alemana Universidad del Desarrollo, Santiago, Chile.&#xD;
      Additional sites may be set up as required.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 11, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological Recovery</measure>
    <time_frame>18 months</time_frame>
    <description>Processing speed, assessed on the oral Symbol Digit Modalities Test (SDMT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain Imaging</measure>
    <time_frame>18 months</time_frame>
    <description>White matter free water measured on diffusion MRI brain imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Neurocognitive Impairment, Mild</condition>
  <arm_group>
    <arm_group_label>Study Medication Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-monthly supplies of atorvastatin 40mg on top of standard care for a period of 18 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care for a period of 18 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>40mg atorvastatin + standard care daily for 18 months.Atorvastatin 40mg has TGA approval for general marketing for the treatment of hypercholesterolaemia and cardiovascular prevention under a number of manufacturer names.The study medication selected will be the atorvastatin 40mg (Apotex) which is scored, and allows down-titration to 20mg should a participant develop symptoms.The study medication will be packaged, labelled and dispensed directly to particpants by the Syntro Health pharmacy in Australia. A comparable atorvastatin 40mg is being sourced in Chile, and will be dispensed from the pharmacy of the Clínica Alemana de Santiago.</description>
    <arm_group_label>Study Medication Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <description>Standard care for neurological symptoms as a result of COVID-19 infection.</description>
    <arm_group_label>Standard Care Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  History of COVID-19 that is confirmed by a positive polymerase-chain-reaction (PCR)&#xD;
             test&#xD;
&#xD;
          -  Any ongoing neurological symptoms as a result of COVID-19 (e.g. problems with memory,&#xD;
             concentration, sleep disturbance and fatigue) that are identified through&#xD;
             administration of the checklist of symptoms on the Somatic and Psychological Health&#xD;
             Report (SPHERE) questionnaire, or reported loss of smell (anosmia)&#xD;
&#xD;
          -  Able to fully participate in all procedures, including cognitive assessments&#xD;
&#xD;
          -  Able and willing to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of dementia and/or significant cognitive impairment on screening (i.e. Blind&#xD;
             Montreal Cognitive Assessment [MoCA] score &lt;19/22)&#xD;
&#xD;
          -  Severe co-morbid medical or psychiatric condition that prevents participation&#xD;
&#xD;
          -  History of traumatic brain injury with loss of consciousness (&gt;30 mins) within the&#xD;
             last 2 years&#xD;
&#xD;
          -  Ongoing long-term use for a clear indication (e.g. secondary cardiovascular prevention&#xD;
             in high-risk individuals) or any contraindication (e.g. previous adverse reaction) of&#xD;
             statin use&#xD;
&#xD;
          -  Evidence of severe or significant liver disease, defined as any of the following:&#xD;
             acute viral hepatitis; chronic active hepatitis; chronic active hepatitis; cirrhosis;&#xD;
             or elevated biochemical function markers i.e. ALT or AST &gt;3x the ULN or eGFR&#xD;
             &lt;30mL/min/1.73m2&#xD;
&#xD;
          -  Creatine kinase (CK) levels &gt; 2x upper limit of normal (ULN)&#xD;
&#xD;
          -  Female of child-bearing potential that is unable or unwilling to use reliable method&#xD;
             of contraception, breastfeeding, or planning a pregnancy&#xD;
&#xD;
          -  For a sub-group of participants undergoing MRI - any contraindication to MRI due to&#xD;
             metallic body parts or claustrophobia&#xD;
&#xD;
          -  Medical history of a disorder that might, in the opinion of the attending clinician,&#xD;
             put the participant at significant risk if they were to participate in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Anderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Anderson, MD</last_name>
    <phone>+61 2 8052 4521</phone>
    <email>canderson@georgeinstitute.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Craig Anderson, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The George Institute for Global Health</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clinical trial</keyword>
  <keyword>COVID-19</keyword>
  <keyword>neurological symptoms</keyword>
  <keyword>atorvastatin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 12, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT04904536/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

